Iconic Red Mushroom Faces FDA Ban – Here’s Why

Federal regulators have targeted a rapidly growing segment of the psychoactive edibles market, issuing warnings about products containing Amanita muscaria, the iconic red-capped mushroom steeped in folklore and marketed as a legal psychedelic. The Food and Drug Administration (FDA) recently declared that compounds in the mushroom do not meet safety standards, signaling potential disruptions for manufacturers and retailers alike.

Amanita muscaria, also known as "fly agaric," has captured the imagination of cultures worldwide for centuries. From fairy tale illustrations to video game references, its distinctive red cap with white spots is instantly recognizable. Unlike psilocybin mushrooms, which are controlled substances, Amanita muscaria remains legal, often promoted as a nootropic or microdosing ingredient for anxiety relief and cognitive enhancement.

However, the mushroom’s safety profile is now under fire. The FDA’s investigation followed reports of hospitalizations and suspected deaths linked to Amanita-based products. In a letter to food manufacturers, the agency emphasized that muscimol, ibotenic acid, and muscarine—active compounds in the mushroom—pose risks to public health and have not been approved for food use.

The turning point came earlier this year when poison centers nationwide reported cases of adverse reactions to Amanita-infused chocolates and gummies, notably those marketed under the brand Diamond Shruumz. Testing revealed that these products not only contained muscimol but were also laced with synthetic psilocybin, prescription drugs like pregabalin, and the herbal supplement kava.

Prophet Premium Blends, the California-based company behind the products, issued a recall following the reports. Christian Rasmussen, owner of MN Nice Botanicals, a retailer of Amanita products, described the FDA's decision as a "huge obstacle" for the industry. He suggested that safety issues may stem from adulterated products rather than the mushroom itself.

The FDA has multiple tools to enforce its decision, including initiating recalls, seizing products, or seeking court orders to halt sales. While the agency has not classified Amanita muscaria as a controlled substance, such a move could shift enforcement to the Drug Enforcement Administration (DEA).This could have wide-reaching implications for the entire psychoactive edibles market, said Eric Leas, an epidemiologist at the University of California, San Diego.

For now, the FDA’s warning primarily affects products sold in stores and online, leaving personal cultivation and use untouched. This parallels the regulatory gray area for hemp-derived compounds like Delta-9 THC and CBD, which also face scrutiny but remain widely available.

Critics of the Amanita muscaria edibles market argue that its rapid growth has outpaced scientific research and regulatory oversight. Many products are sold in colorful, psychedelic-themed packaging that some fear could appeal to children.

The problem with these products is that we just don’t know what’s in them, said Dr. Mason Marks, a law professor and expert on psychedelics regulation. Inaccurate labeling and undisclosed additives are serious concerns.

Advocates for stricter oversight point to the mushroom’s dissociative and sometimes unpleasant effects at high doses, which target GABA receptors rather than the serotonin pathways affected by psilocybin. Despite anecdotal claims of benefits for anxiety, sleep, and addiction recovery, clinical evidence supporting these uses is scarce.

The FDA's decision has left Amanita muscaria product manufacturers and retailers scrambling. Psyched Wellness, a company affected by the ruling, noted that safe preparation methods could reduce the mushroom’s undesirable effects, but these practices lack formal recognition from food safety authorities.

This is where consumer demand moves faster than the law, said Shawn Hauser, a lawyer specializing in psychedelics and natural products. Without proper regulation and education, public safety issues will arise.

For now, the industry faces a critical juncture. Whether the FDA ramps up enforcement or takes a lighter touch remains to be seen, but the crackdown has already sparked uncertainty in a once-thriving market.

Should the FDA ban psychoactive edibles containing Amanita muscaria? Vote now!